Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • mario_themario mario_themario Mar 5, 2013 3:40 PM Flag

    JP Morgan weighs in

    So much for a pop on the announcement. They must have talked to Adam.

    UPDATE: JP Morgan Cuts PT to $7 on Arena Pharmaceuticals on Belviq Launch Concerns
    3:05p ET March 5, 2013 (Benzinga) JP Morgan maintained Arena Pharmaceuticals (NASDAQ: ARNA) with a Neutral rating and lowered the price target from $8.00 to $7.00.

    JP Morgan commented, "We continue to see few signs that the early launch of Belviq will avoid the problems VVUS is currently experiencing with its weight loss drug, Qsymia (including slow uptake and a meaningful number of pts not filling their prescription due to a relatively high out-of-pocket cost). In fact, Belviq could well experience a more lackluster launch vs. Qsymia given the drug's higher price and more modest level of efficacy. Maintain Neutral."

    Arena Pharmaceuticals closed at $8.34 on Monday.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The funny thing is I'm long the stock and just posted an analyst price target and for that I get 8 thumbs down. I never said I agreed with it. What a sensitive group. Get used to negative articles, they won't stop today. I sometimes wonder if there are any investors on this board. I expect it to languish around these levels and expect to see it rise in a year. I left the position and haven't sold because I expect it to run slowly and a buyout can happen at any time. I'd rather be in than out.

    • IMO, the analysts continue to misjudge this as just another weight loss drug, when it is more than that. Belviq will be used by people with serious weight problems and other underlying health issues which prevent them from using traditional weight loss meds. Add in the other applications for variations on Belviq and ARNA will do fine.

    • hedge_risk@ymail.com hedge_risk Mar 5, 2013 3:59 PM Flag

      They are VVUS' investment banker - welcome to Wall St. :)

    • Now you / well all know whom the "trapped" short is!!! LMAO!!!
      BRM.

      Sentiment: Strong Buy

    • Looks like other investors haven't been paying too much attention to the JPM move...at least at this point.

    • Us ole longs could do not give a rats asz what jpm says ------ arent they the very ones that were in financial distress not long ago ?? and still half what they were a few yrs ago?? man im up 700% arna -- jpm might need to be watching and learning --- just sayin

      Sentiment: Strong Buy

    • They never disclosed what stock they naked shorting they and lost so much on wasn't it 9 billion on one stock and it was a small Bio and ever since the news hit the wires of there loss, crammer has been pounding the table and trying to get investors to sell Arena. There are several of funds that are in deep and the SEC is looking the other way in order to protect them. There are very big forces involved here.

      Sentiment: Strong Buy

    • inaccurate

      Sentiment: Hold

      • 3 Replies to jdietz4444
      • JP Morgan maintained Arena Pharmaceuticals (NASDAQ: ARNA) with a Neutral rating and lowered the price target from $8.00 to $7.00 .
        JP Morgan commented, "We continue to see few signs that the early launch of Belviq will avoid the problems VVUS is currently experiencing with its weight loss drug, Qsymia (including slow uptake and a meaningful number of pts not filling their prescription due to a relatively high out-of-pocket cost). In fact, Belviq could well experience a more lackluster launch vs. Qsymia given the drug's higher price and more modest level of efficacy. Maintain Neutral."
        Arena Pharmaceuticals closed at $8.34 on Monday.

      • He is not lying that did come up on the live news at 5:45. But I would like to explain something. When a big fish decides he wants into a stock and now sees the value. Remember that ARNA was at the JP Morgan conference a couple days ago. They will be very cautious with the wording and the price targets so they can acquire a position.

        I was in a stock one time the JP Morgan initiated coverage and set a price target 30% lower then it was trading at. Over the coarse of a couple months JP Morgan acquired millions of shares at that lower price range while the stock traded around that target. Once good news came out and they had acquired their millions of shares they over the coarse of a year kept upping their price targets and their rating on the stock. In a couple years the stock sits at 200% higher then their original coverage price target.

        This is what I believe we will see going on for a while. Sorry but it is true. The Wall Street machine is not in this stock and as the stock starts to perform they will want in but they don't want to chase it or drive it up. So they will initiate coverage or confirm existing opinions on ARNA. All in order to try and keep the stock price down while they acquire shares at a cheaper price. They want in so they can make money selling those shares to their clients down the road when the stock is firing on all cylinders and they have a price target on it at 18 and they are selling to their clients at 15.

      • What's inaccurate? This just poped up on my TD acct. JP looks like they pulled this out of their you know what. Not a lot of technical analysis, just their gut from the tone of the opinion, especially the last sentence. I guess they forgot about Q's REMS + limited distribution which won't impact B nor the larger sales force + the staff working on insurer coverage. Their rating is a joke.

 
ARNA
1.57-0.04(-2.48%)Feb 5 4:00 PMEST